$ASND · Ascendis Pharma A/S SEC Filings
Position Tracker tracks 2 SEC EDGAR filings for Ascendis Pharma A/S ($ASND) from November 12, 2026 through November 12, 2026, including 0 Form 10-K annual reports, 0 Form 10-Q quarterly earnings reports, 0 Form 8-K current event disclosures, and 0 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$ASND 6-K — Ascendis Pharma A/S
Ascendis delivered its first sustained profitability inflection, with YORVIPATH sales more than doubling and a near-term EU catalyst for TransCon CNP.
$ASND 6-K — Ascendis Pharma A/S
Ascendis's first sustained commercial profitability marks a turning point for the TransCon platform's revenue story.